ON THE PATH
TOWARD THE POSSIBLE

At Flare, we are building a pipeline of drug discovery programs from select transcription factors with robust genetic and biologic validation, initially focused on precision oncology. With our understanding of the switch site, we have a unique way to identify druggable pockets that are central to TF conformational control, and thus to its function. This leads to our highly differentiated pipeline of drug programs that opens a new path for targeting the central genetic drivers of cancer and other diseases.

Further, we are applying the switch site paradigm to early discovery programs in neurology, immunology/inflammation and rare genetic disorders driven by transcriptional dysregulation.